T
Thomas Brunner
Researcher at University of Konstanz
Publications - 511
Citations - 26076
Thomas Brunner is an academic researcher from University of Konstanz. The author has contributed to research in topics: Apoptosis & Medicine. The author has an hindex of 75, co-authored 448 publications receiving 23438 citations. Previous affiliations of Thomas Brunner include University Medical Center Freiburg & University of Oxford.
Papers
More filters
Journal ArticleDOI
Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies.
TL;DR: An overview on oesophageal toxicity from conventional and stereotactic fractionated radiotherapy to the thoracic area in general and available attempts to predict the risk of oesphageal side effects from dosimetric parameters of SBRT are provided.
Journal ArticleDOI
Local synthesis of immunosuppressive glucocorticoids in the intestinal epithelium regulates anti-viral immune responses.
TL;DR: Findings show that virus-induced intestinal GC synthesis is controlled by LRH-1 and SHP, and that local steroidogenesis contributes to the maintenance of intestinal immune homeostasis, and could represent an interesting therapeutic target in the treatment of inflammatory disorders.
Journal ArticleDOI
A phage display system for detection of T cell receptor-antigen interactions
Takebumi Onda,Drake LaFace,Gottfried Baier,Thomas Brunner,Nakayuki Honma,Toshifumi Mikayama,Amnon Altman,Douglas R. Green +7 more
TL;DR: While the binding specificities exhibited by these TCRs are unusual, they provide a novel perspective from which to study the specific binding interactions that constitute TCR antigen binding.
Journal ArticleDOI
Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.
TL;DR: SBRT for primary renal cell cancer appears a viable option for medically inoperable patients but future research needs to better define patient selection criteria and the detailed practice of SBRT.
Journal ArticleDOI
Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries
Stephanie G. C. Kroeze,C. Fritz,L. Basler,Eleni Gkika,Eleni Gkika,Thomas Brunner,Anca-L. Grosu,Anca-L. Grosu,Matthias Guckenberger +8 more
TL;DR: Although evidence for safety and efficacy of concurrent SBRT and targeted agents is limited, it is regularly performed outside of clinical trials and should be practiced with caution and BRAF inhibitors should be paused at least 1 week before S BRT.